Navigation Links
Over 600 Surgeons Certified to use TruFUSE(R) to Treat Back Pain Sufferers
Date:11/27/2007

ents. Only one of the seven migration cases required revision surgery for recurrence of back pain. There were no serious complications noted.

TruFUSE represents a new surgical option for many back pain sufferers who do not yet qualify for major surgery. It may be used to treat a variety of back problems, including augmentation of other procedures for any location from C2-C3 to L5-S1. Compared to many existing methods, TruFUSE is generally less invasive, less destructive, less complicated, less expensive and subjects the patients to relatively minimal risk.

TruFUSE has been used on select patients since March 2006, and went into limited distribution in August 2006.

For more information on TruFUSE, please visit the Web site at http://www.trufuse.com or call (813) 318-0565 ext. 216.


'/>"/>
SOURCE minSURG Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine news :

1. MedHelp to Add Top Stanford Surgeons and Specialized Forums to Online Health Community
2. Surgeons Remove Gallbladder Through Vagina
3. CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress
4. Cosmetic Surgeons Gather in Dubai for World Congress, Hospital Opening
5. Starion Instruments Launches Next-Generation Tissue Ligating Shears at the American College of Surgeons Clinical Congress
6. Patients should ask surgeons about using honey to heal wounds
7. Expert Neurosurgeons and Neuro-oncologists to Speak at 6th Annual Brain Tumor Awareness Day Convention
8. Survey shows gender differences are factor when surgeons in training choose a subspecialty
9. American College of Surgeons Comments on JAMA Article on Surgeon Shortage
10. Holiday Hand Safety 101: Hand Surgeons Offer Tips for a Safe Carving Season
11. Verdict One Releases Directory of Board Certified Attorneys for Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...sion May Be Revealed Friday, January 9 , , WAS... Service Employees International Union (SEIU) Pres... SEIU International Executive Board to discuss the...re members out of SEIU United Healthcare Workers-W...d the final decision until tomorrow. , , Accord...
(Date:1/8/2009)...pts Prenatal Solution Key Factor in Decision for F...RLANDO, Fla., Jan. 8 All...LLC, one of the largest multi-specialty group prac... the Allscripts Enterprise(TM) Electronic Health R...cians in 18 offices across Central Florida. , ...
(Date:1/8/2009)...d., Jan. 8 Hanger Ortho...ounce that throughout the fourth quarter of 2008 i...nter, Rocky Mountain Orthotic-Prosthetics Center, ..., First Coast Orthotics & Prosthetics, and Ort...itions add patient care centers to existing market...
(Date:1/8/2009)... Jan. 8 The Pew Charita...been named director, chemical and food safety prog...ogram. Olson, who was formerly deputy staff direct...Environment and Public Works, brings nearly 25 yea...mer advocacy to Pew. , , "We are excited to be...
Breaking Medicine News(10 mins):Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2
...n predict the mortality risk in patients hospitali...ndings // of a recent study. According to research...r the treatment of acute heart failure and offers ...ality risk upon hospital admission and quickly dec...
...arch has indeed unleashed several social and moral... and individuals to introspect within themselves./...n the understanding of human development. A recen...am from the University of Pittsburg, has opened pe...
...ondhand tobacco smoke could eventually lead to lun...// later in life say researchers based on findings...23,000 people who had either never smoked themselv... years participated in the study. Results showed p...
...rt disease risk factors may reduce the risk of dem...nt study // which shows that cardiovascular risk f...e risk of dementia in old age. Risk factors for c...sterol, hypertension, diabetes and smoking. Each o...
Other Medicine News:
(Date:1/7/2009)...PRNewswire/ -- ImQuest Life Sciences announced tod... to the Food and Drug Administration to initiate h...e HIV inhibitor IQP-0410. ImQuest anticipates init...of 2009. IQP-0410 is a novel small molecule inhibi... reverse transcriptase inhibitor (NNRTI). The comp...
(Date:1/7/2009)...uary 7 Circassia Ltd, a specialty,...critical care, today,announced that following suc...s ToleroMune(R) anti-allergy technology, the compa...rther phase II clinical trial in cat allergy. The,... 120 patients with confirmed,cat allergies, and a...
(Date:1/6/2009)...RNewswire/ -- In recent controlled studies conduct..., scientists found that the patented ingredient in...y proven ingredient to increase levels of nitric o...trate/nitrate (NOx) in human subjects. , , Nitr...ease in blood flow to the skeletal muscles. This ...
(Date:1/6/2009)... Cequent Pharmaceuticals, a pionee...RNAi-based treatments to prevent and treat human d...mpleted a successful toxicology study of its candi...peutic targeting the primary oncogene (beta-cateni.... FAP is an inherited gastrointestinal disease tha...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 1Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 2Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 3China Medicine Releases White Paper on Developing Recombinant Aflatoxin Detoxifizyme 23558 1China Medicine Releases White Paper on Developing Recombinant Aflatoxin Detoxifizyme 23558 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 1Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 3Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 1Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 2Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 3Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 4
...Scheduled for Friday, May 4, at 9:00 a.m.,Eastern .../PRNewswire-FirstCall/ --,Medivation, Inc. today a...subgroups of Alzheimer,s disease patients in the C...on showed that both,subgroups were improved compar...acy endpoints studied. , The mean drug-placebo dif...
...hows Promise As an Adjuvant for Vaccines,against A... 07, 2007 /PRNewswire-FirstCall/ -- IR,BioSciences...ata,from its influenza vaccine adjuvant study bein...ates Homspera elevates host,immune responsiveness ...results are from an ongoing study, and are a stron...
Other Medicine Technology:Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 2Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 3Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 4Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 5IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 2IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 3IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 4
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium.
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches.
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches.
Left angled 5 mm blunt hook. Overall length: 9.9 inches.
Medicine Products: